US 12,433,908 B2
Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development
Ryan Dellinger, Azusa, CA (US); Troy Rhonemus, Mission Viejo, CA (US); Mark Morris, Irvine, CA (US); Dietrich Conze, Garrett Park, MD (US); and Amy Boileau, Libertyville, IL (US)
Assigned to ChromaDex Inc., Los Angeles, CA (US)
Filed by ChromaDex, Inc., Irvine, CA (US)
Filed on Nov. 30, 2022, as Appl. No. 18/060,257.
Application 18/060,257 is a division of application No. 17/114,864, filed on Dec. 8, 2020, granted, now 11,524,022.
Application 17/114,864 is a continuation of application No. 15/488,215, filed on Apr. 14, 2017, granted, now 10,857,172, issued on Dec. 8, 2020.
Claims priority of provisional application 62/322,460, filed on Apr. 14, 2016.
Prior Publication US 2023/0201233 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/706 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A23L 33/15 (2016.01); A23L 33/19 (2016.01); A61K 31/4415 (2006.01); A61K 31/455 (2006.01); A61K 31/51 (2006.01); A61K 31/525 (2006.01); A61K 31/7064 (2006.01); A61K 45/06 (2006.01); A61K 47/42 (2017.01)
CPC A61K 31/706 (2013.01) [A23L 33/10 (2016.08); A23L 33/15 (2016.08); A23L 33/19 (2016.08); A23L 33/30 (2016.08); A23L 33/40 (2016.08); A61K 31/4415 (2013.01); A61K 31/455 (2013.01); A61K 31/51 (2013.01); A61K 31/525 (2013.01); A61K 31/7064 (2013.01); A61K 45/06 (2013.01); A61K 47/42 (2013.01); A23V 2002/00 (2013.01)] 13 Claims
 
1. An infant formula composition comprising at least one nicotinyl riboside compound, or salt thereof, wherein said nicotinyl riboside compound comprises nicotinamide riboside (NR, I), and optionally at least one nicotinyl riboside compound selected from the group consisting of nicotinic acid riboside (NAR, II), reduced nicotinamide riboside (NRH, IV), reduced nicotinic acid riboside (NARH, V), nicotinamide riboside triacetate (NRTA, VI), nicotinic acid riboside triacetate (NARTA, VII), reduced nicotinamide riboside triacetate (NRH-TA, VIII), and reduced nicotinic acid riboside triacetate (NARH-TA, IX); together with an acceptable excipient, diluent, or carrier, wherein the total amount of nicotinyl riboside compound or salt thereof in the infant formula composition is about 1,500 ug to about 10,000 ug per 100 kilocalories of the infant formula composition.